Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2025 02:30 ET | Source: eleva GmbH

Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers

Eleva is advancing CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of SAD evaluation in healthy volunteers
July 07, 2025 02:30 ET | Source: eleva GmbH

Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers

First-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany,...